Catalyst Wire Dossier Catalyst Wire Dossier

Aflibercept 8 mg

aflibercept · Regeneron Pharmaceuticals; Sanofi
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Aflibercept 8 mg, covering 2026-02-20 to 2026-02-20. Get the full timeline:

Most recent: Clinical Trial Update: Retrospective Multicenter Real-world Observational Study of Switching to Aflibercept 8 mg in Patients With Refractory or Dependent Exudative Age-related Macular Degeneration

See pricing